News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Alterity Therapeutics Limited (ASX:ATH) has applied for the quotation of 354,203 new ordinary shares on the ASX, which were issued on August 14, 2026, after the exercise of options under the security code ATHO. These options were exercised at AUD $0.50 per security and …
Royal Bank of Canada significantly increased its stake in Weatherford International PLC by 43.8% in the first quarter, now owning 60,324 shares. Institutional investors and hedge funds collectively hold 97.23% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average …
Alterity Therapeutics Limited (ASX:ATH) saw its share price decline by 4.46% to $0.535 during the latest trading session, with the stock trading within a daily range of $0.520 to $0.565. The company's market capitalization stands at $122.06M, and it recorded a trading volume of …
Alterity Therapeutics has secured a new U.S. patent for its lead clinical asset, ATH434, extending its protection to at least 2045. This patent significantly strengthens the intellectual property for ATH434, which is currently in development for Multiple System Atrophy (MSA) and Parkinson’s disease, as …
Alterity Therapeutics announced that the U.S. Patent and Trademark Office has granted a new composition of matter patent for ATH434, extending its protection to at least 2045. This patent covers the crystalline mesylate form of ATH434 and methods for treating neurological conditions, strengthening its …
Alterity Therapeutics has been granted a new U.S. composition of matter patent for its lead clinical asset, ATH434, extending its protection to at least 2045. This patent significantly enhances the commercial potential of ATH434, particularly as the company prepares for Phase 3 trials in …
Alterity Therapeutics has secured a key US patent for its lead asset, ATH434, covering its crystalline form and methods for treating neurological conditions. This patent significantly strengthens the company's intellectual property portfolio and extends market protection until at least 2045. The drug is slated …
Alterity Therapeutics has been granted a key US patent for its lead clinical asset, ATH434, which is designed to treat neurodegenerative diseases like multiple system atrophy (MSA) and Parkinson's disease. This patent extends protection until at least 2045, significantly enhancing the drug's commercial potential …
Tandy Leather Factory (NASDAQ: TLF) reported a significant turnaround in Q2 2026, achieving a net income of $0.4 million and EPS of $0.05, compared to a net loss in the previous year. This profitability was driven by a substantial increase in gross margins to …
Tandy Leather Factory (TLF) reported a 1.5% increase in Q2 2026 revenue to $18.0 million, compared to $17.8 million in the prior year. The company swung to a net income of $0.4 million from a net loss of $0.2 million, with basic and diluted …
Tandy Leather Factory (Nasdaq: TLF) reported strong second-quarter 2026 results, with revenues increasing by 1.5% to $18.0 million and gross profit reaching $11.7 million, pushing the gross margin to 64.8%. The company swung to a net income of $0.4 million, or $0.05 earnings per …
Tandy Leather Factory, Inc. (Nasdaq: TLF) announced its financial results for the second quarter of 2026, reporting revenues of $18.0 million, a 1.5% increase from 2025, and a net income of $0.4 million compared to a net loss in the prior year. The company …
Craig-Hallum initiated coverage on Alterity Therapeutics (NASDAQ:ATHE) with a "buy" rating and a $12.00 price target, suggesting a potential upside of over 160% from its current trading price of $4.54. The firm sees Alterity's drug ATH434 for multiple system atrophy as a high-risk, high-reward …
Alterity Therapeutics (ASX:ATH) saw its shares rise as its lead drug candidate, ATH434, progresses towards a pivotal Phase 3 trial for Multiple System Atrophy (MSA) after securing positive FDA interactions. The company received formal FDA End-of-Phase 2 meeting minutes confirming a registrational pathway and …
This article provides details about an EDGAR Form 6-K filing by ALTERITY THERAPEUTICS LTD. The filing, with accession number 0001437749-26-026626, was filed on August 10, 2026, and includes various documents and graphics. The company's mailing and business address in Melbourne, Australia, is also listed.
Alterity Therapeutics Limited has filed a Form 6-K Current Report (Foreign Issuer) with the SEC on August 10, 2026, detailing an application for quotation of securities. This report is incorporated by reference into several of the company's registration statements. The filing indicates a neutral …
Weatherford International PLC (NASDAQ:WFRD) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $113.56, significantly above its current trading price of $86.82. The company's recent quarterly results showed revenue exceeding estimates but EPS falling short, alongside …
Alterity Therapeutics (ASX: ATH), a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026. The presentation will highlight the company's lead asset, ATH434, which has shown efficacy …
Alterity Therapeutics (NASDAQ: ATHE) announced that CEO David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026, at 1:30 p.m. ET. The company is focused on developing therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders, …
Renaissance Technologies LLC significantly reduced its stake in Weatherford International PLC by selling 174,300 shares, now holding 65,953 shares valued at approximately $6.24 million. Despite the reduction, institutional investors collectively own a substantial 97.23% of WFRD. The company recently reported quarterly EPS of $0.55, …
Search by ticker symbol or company name and select a result to open its chart.